IN2012DN06631A - - Google Patents

Info

Publication number
IN2012DN06631A
IN2012DN06631A IN6631DEN2012A IN2012DN06631A IN 2012DN06631 A IN2012DN06631 A IN 2012DN06631A IN 6631DEN2012 A IN6631DEN2012 A IN 6631DEN2012A IN 2012DN06631 A IN2012DN06631 A IN 2012DN06631A
Authority
IN
India
Prior art keywords
yloxy
methyl
isoxazol
pyran
piperidin
Prior art date
Application number
Other languages
English (en)
Inventor
Hirohide Noguchi
Nobuaki Waizumi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IN2012DN06631A publication Critical patent/IN2012DN06631A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN6631DEN2012 2010-02-16 2011-02-09 IN2012DN06631A (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30492110P 2010-02-16 2010-02-16
PCT/IB2011/050548 WO2011101774A1 (en) 2010-02-16 2011-02-09 (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors

Publications (1)

Publication Number Publication Date
IN2012DN06631A true IN2012DN06631A (cs) 2015-10-23

Family

ID=43904611

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6631DEN2012 IN2012DN06631A (cs) 2010-02-16 2011-02-09

Country Status (15)

Country Link
US (1) US20120041026A1 (cs)
EP (1) EP2536713A1 (cs)
JP (1) JP2013519722A (cs)
KR (1) KR20120123089A (cs)
CN (1) CN102762554A (cs)
AR (1) AR080172A1 (cs)
AU (1) AU2011216950A1 (cs)
CA (1) CA2788656A1 (cs)
IN (1) IN2012DN06631A (cs)
MX (1) MX2012008721A (cs)
SG (1) SG183111A1 (cs)
TW (1) TW201141856A (cs)
UY (1) UY33225A (cs)
WO (1) WO2011101774A1 (cs)
ZA (1) ZA201206469B (cs)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US10583138B2 (en) 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
ES2618494T3 (es) 2011-05-18 2017-06-21 Raqualia Pharma Inc Forma polimórfica del ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2-benzisoxazol-3-il]oxi}metil)piperidin-1-il]metil}-tetrahidro -2H-piran-4-carboxílico
CA2890861C (en) * 2012-11-21 2021-03-30 Raqualia Pharma Inc. Polymorphic forms of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
SG11201507763RA (en) 2013-03-20 2015-10-29 Suven Life Sciences Ltd 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
KR101824154B1 (ko) 2013-12-16 2018-03-14 수벤 라이프 사이언시스 리미티드 5-ht4 수용체 작용제로서 인다졸 화합물
BR112016024213A2 (pt) * 2014-05-20 2017-08-15 Raqualia Pharma Inc sal derivado de benzisoxazol, método para tratamento de condições de doença mediadas por atividade de receptor 5-ht4, processo para preparação e uso do sal
US9957257B2 (en) 2015-02-13 2018-05-01 Suven Life Sciences Limited Amide compounds as 5-HT4 receptor agonists
CN117796401A (zh) * 2023-12-25 2024-04-02 江苏万隆化学有限公司 一种含2-羟基-6-氟苯甲酸甲酯中间体抗菌剂的制备工艺

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2104297C (en) 1991-02-27 2003-05-27 Boyd Lynn Harrison 4-sulfanimide-quinoline nmda antagonists
US5750542A (en) * 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
ES2187518T3 (es) * 1992-11-23 2003-06-16 Aventis Pharma Inc 3-(aminoalquilamino)-1-2-benzisoxazoles sustituidos y compuestos relacionados.
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
TR199800531T1 (xx) 1995-09-29 1998-06-22 Glaxo Wellcome Spa NMDA antagonistleri olarak tetrahidrokinolinler.
IL126003A0 (en) 1996-04-10 1999-04-11 Hoechst Marion Roussel Inc Spiro [cyclopent [b] indole-piperidines] and n-[phenyl-hydrazon intermediates for their preparation both being acetyl cholinesterase and mao inhibitors
ATE207483T1 (de) 1996-04-12 2001-11-15 Aventis Pharma Inc Isatinderivate als acetylcholinesterase- inhibitoren und analgetika
DE69715865T2 (de) 1996-07-01 2003-08-07 Schering Corp., Kenilworth Muscarin-antagonisten
PL331536A1 (en) 1996-08-15 1999-07-19 Schering Corp Muscarinic antagonists with an etheric bond
WO1998014427A1 (en) 1996-09-30 1998-04-09 Hoechst Marion Roussel, Inc. Nmda (n-methyl-d-aspartate) antagonists
CN1572299A (zh) 1998-09-30 2005-02-02 武田药品工业株式会社 改善膀胱排泄能力的药物
DK1362844T3 (da) 2001-01-26 2008-04-14 Btg Int Ltd Benzylaminanalog
US7375136B2 (en) 2001-03-08 2008-05-20 Emory University pH-dependent NMDA receptor antagonists
EP1390034A4 (en) 2001-04-03 2005-07-13 Merck & Co Inc NMDA / NR2B NONARYL-HETEROCYCLO AMIDYL N-SUBSTITUTE ANTAGONISTS
BR0211393A (pt) 2001-07-24 2004-08-17 Richter Gedeon Vegyeszet Derivados de piperidina como antagonistas de receptor nmda
JP3927228B2 (ja) 2003-06-04 2007-06-06 メルク エンド カムパニー インコーポレーテッド Nmda/nr2b拮抗物質としての3−フルオロ−ピペリジン
GB0316094D0 (en) 2003-07-09 2003-08-13 Neuropharma Sa Acetylcholinesterase dual inhibitors
CN102357062B (zh) * 2004-03-03 2015-08-05 雷文斯治疗公司 用于肉毒毒素的局部施用和透皮递送的组合物和方法
HU227119B1 (en) 2004-07-29 2010-07-28 Richter Gedeon Nyrt Indole and benzimidazole carboxylic acid amide derivatives and pharmaceutical compositions containing them
HUP0401523A3 (en) 2004-07-29 2007-05-02 Richter Gedeon Vegyeszet Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them
HU226977B1 (en) 2004-07-29 2010-04-28 Richter Gedeon Nyrt Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them
HUP0401522A2 (en) 2004-07-29 2006-04-28 Richter Gedeon Vegyeszet New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
HU227000B1 (en) 2004-07-29 2010-04-28 Richter Gedeon Nyrt Nmda receptor antagonist benzoyl urea derivatives, and pharmaceutical compositions containing them
TW200621677A (en) 2004-09-21 2006-07-01 Astellas Pharma Inc Cyclic amine derivative or salt thereof
WO2006039767A1 (en) 2004-10-15 2006-04-20 Universidade Federal Do Rio De Janeiro-Ufrj Piperidinic derivatives, pharmaceutic compositions containing the same and preparation processes
JP4970290B2 (ja) * 2005-02-25 2012-07-04 ファイザー株式会社 ベンズイソキサゾール誘導体
US20090124600A1 (en) 2005-04-19 2009-05-14 Layton Mark E N-Alkyl-Azacycloalkyl NMDA/NR2B Antagonists
CA2617104A1 (en) 2005-07-29 2007-02-08 Regents Of The University Of Minnesota Amyloid beta receptor and uses thereof
WO2007107846A1 (en) 2006-03-20 2007-09-27 Council Of Scientific And Industrial Research A pharmaceutical composition useful as acetyl cholinesterase inhibitors
ES2288406B1 (es) 2006-04-20 2008-12-16 Universidad De Barcelona Compuestos inhibidores de acetilcolinesterasa para el tratamiento de la enfermedad de alzheimer.
ATE502026T1 (de) 2006-12-20 2011-04-15 Abbott Healthcare Products Bv Verbindungen mit kombinierten cannabinoid-cb1- antagonismus und acetylcholinesterasehemmung
US7605265B2 (en) 2007-01-22 2009-10-20 Biotechnology Research Corporation Ltd. Heterodimers and methods of using them
PL2152709T3 (pl) 2007-05-01 2012-07-31 Concert Pharmaceuticals Inc Związki morfinanu
CN104844678B (zh) 2007-05-11 2018-02-09 香港科技大学 具有神经保护和增强记忆活性的受体调节剂
EA201070077A1 (ru) 2007-06-29 2010-08-30 Эмори Юниверсити Антагонисты nmda-рецепторов с нейропротективным действием
US8129428B2 (en) 2007-09-12 2012-03-06 Virginia Tech Intellectual Properties, Inc. Insecticidal carbamates exhibiting species-selective inhibition of acetylcholinesterase (AChE)
GB2470495B (en) 2008-01-16 2012-12-26 Biotechnology Res Corp Ltd Oxazolidine derivatives as NMDA antagonists
EA014100B1 (ru) 2008-02-21 2010-08-30 Общество С Ограниченной Ответственностью "Валексфарм" Производные 2,4-диаминопиридина, фармацевтическая композиция, лекарственное средство на их основе для лечения или предупреждения заболеваний и нарушений, вызванных гиперактивацией nmda-рецепторов и/или в качестве стимуляторов когнитивных функций и способ лечения
CN101440061B (zh) 2008-04-08 2010-12-08 温州医学院 一类具有抑制乙酰胆碱酯酶活性的芳基吡啶酮类衍生物
WO2009129181A1 (en) 2008-04-14 2009-10-22 Concert Pharmaceuticals Inc. Propanediol-dicarbamate derivatives
CA2722776A1 (en) 2008-05-09 2009-11-12 Emory University Nmda receptor antagonists for the treatment of neuropsychiatric disorders

Also Published As

Publication number Publication date
CN102762554A (zh) 2012-10-31
CA2788656A1 (en) 2011-08-25
KR20120123089A (ko) 2012-11-07
TW201141856A (en) 2011-12-01
SG183111A1 (en) 2012-09-27
AR080172A1 (es) 2012-03-21
EP2536713A1 (en) 2012-12-26
MX2012008721A (es) 2012-08-17
JP2013519722A (ja) 2013-05-30
ZA201206469B (en) 2013-05-29
UY33225A (es) 2011-09-30
US20120041026A1 (en) 2012-02-16
WO2011101774A1 (en) 2011-08-25
AU2011216950A1 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
IN2012DN06631A (cs)
MX2009009429A (es) Analogos de ciclopamina lactama y metodos de uso de los mismos.
BR112012031620A2 (pt) atm acessível para deficiente físico
EP4335501A3 (en) Use of estriol in low doses
SG176656A1 (en) Microorganisms for the production of 1,4-butanediol and related methods
MY179933A (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use thereof
TN2009000185A1 (en) Progesterone receptor antagonists
GB201118864D0 (en) Screen capture
EP3822352A3 (en) Methods and compositions for modulating apolipoprotein(a) expression
MX2014009657A (es) Pilar dental para el soporte de protesis dentales y metodo de fabricacion del mismo.
PH12014500541A1 (en) Various control elements in a hybrid game
NZ603625A (en) A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
AU2011305525A8 (en) Modulators of the GPR119 receptor and the treatment of disorders related thereto
TN2011000653A1 (en) Pharmaceutical compositions and solid forms
MY156946A (en) Composition for decreasing hardness of water
EP4494704A3 (en) Use of cyclic amide derivatives to treat sleep disorders
AU335053S (en) Integrated winchhead
PH12014500538A1 (en) Methods and compositions for treating leukemia
PL401820A1 (pl) Uklad i sposób dezynfekcji i dezodoryzacji systemów gromadzenia odpadów wykorzystujace ozon
IN2014CN00834A (cs)
IN2014CN00817A (cs)
WO2009120381A3 (en) Faucet system and advertising method
UA103263C2 (ru) Способ увеличения полового члена и электромеханический экстендер для его реализации
IN2014DN02984A (cs)
Kim et al. A study on the enhancement of basic scholastic ability applied combined model of cyber home study